Eisai Presents New Research on Epilepsy Pipeline, Portfolio at the 29th International Epilepsy Congress
Looks to Expand Global Epilepsy Product Portfolio
Tokyo, Sept 1, 2011 – (JCN Newswire) – Eisai Co., Ltd. announced today that 35 abstracts highlighting the latest results from studies with its pipeline and portfolio products (perampanel: 5 abstracts, Zonegran(R): 5 abstracts, Zebinix(R): 25 abstracts) were presented at the 29th International Epilepsy Congress which took place in Italy (Rome) between August 28 and September 1, 2011. This research demonstrates Eisai’s commitment to the area of epilepsy, underpinning the company’s product portfolio strategy for the global market.
Epilepsy constitutes an area with significant unmet medical needs. Having positioned epilepsy as a therapeutic area of focus, Eisai offers multiple treatment options in Europe based on its abundant Epilepsy franchise product portfolio, which includes three currently marketed treatments: Zonegran (under license from the originator, Dainippon Sumitomo Pharma Co., Ltd.) and Zebinix (under license from the originator, BIAL-Portela & Ca S.A.), adjunctive therapies for adult patients with partial-onset seizures (including patients with secondary generalization); and Inovelon(R) (under license from the originator, Novartis AG), an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome. In May of this year, the company also submitted an application, which is now under review by the European Medicines Agency (EMA), seeking approval to market its novel AMPA receptor antagonist perampanel as an adjunctive therapy for epilepsy patients with partial-onset seizures.
Eisai presented the findings from two Phase III studies it conducted with a view to obtaining regulatory approval for perampanel and Zonegran for the first time at the IEC. Results of a Phase III study (Study 305) for perampanel for partial-onset seizures showed that once-daily perampanel, 8 mg and 12 mg, produced statistically significant reductions in median seizure frequency compared to placebo among epilepsy patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs. Results of a Phase III study (Study 312) with Zonegran in pediatric epilepsy patients showed that Zonegran was highly tolerable and exhibited potent anti-epileptic effects compared to placebo in partial-onset seizure patients on one or two other anti-epileptic drugs. The results of three pivotal studies with Zebinix in epilepsy patients with partial-onset seizures as well as plans for additional clinical studies with the agent (pediatric patients, monotherapy) were also presented at the IEC.
Eisai is committed to maximizing its product portfolio in the area of epilepsy through both the development of new drugs and the life cycle management which includes indication expansion as it seeks to make further contributions to address the diversified needs of and increase the benefits provided to epilepsy patients and their families.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.co.jp/index-e.html
Eisai Co., Ltd. Public Relations Department, +81-3-3817-5120>
Copyright 2011 JCN Newswire. All rights reserved. www.japancorp.net